These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22149418)

  • 1. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Maggo S; Tan M; Savage R; Ashton J
    Drug Saf; 2012 Jan; 35(1):33-43. PubMed ID: 22149418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Drug Saf; 2011 Sep; 34(9):763-72. PubMed ID: 21830838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres.
    Harrison-Woolrych M; Härmark L; Tan M; Maggo S; van Grootheest K
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1065-72. PubMed ID: 22315148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y; Cornelius V; Fogg C; Kasliwal R; Layton D; Shakir SA
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study.
    Graham DJ; By K; McKean S; Mosholder A; Kornegay C; Racoosin JA; Young J; Levenson M; MaCurdy TE; Worrall C; Kelman JA
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1205-12. PubMed ID: 25044169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.
    Singh S; Loke YK; Spangler JG; Furberg CD
    CMAJ; 2011 Sep; 183(12):1359-66. PubMed ID: 21727225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.
    Prochaska JJ; Hilton JF
    BMJ; 2012 May; 344():e2856. PubMed ID: 22563098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):949-53. PubMed ID: 20602347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
    Nahvi S; Wu B; Richter KP; Bernstein SL; Arnsten JH
    Drug Alcohol Depend; 2013 Sep; 132(1-2):47-52. PubMed ID: 23332438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary benefit-risk assessment of varenicline in smoking cessation.
    Cahill K; Stead L; Lancaster T
    Drug Saf; 2009; 32(2):119-35. PubMed ID: 19236119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of adverse cardiovascular events from varenicline balanced against the benefits in mortality from smoking cessation.
    Kistler CE; Goldstein AO
    Nicotine Tob Res; 2012 Dec; 14(12):1391-3. PubMed ID: 22422928
    [No Abstract]   [Full Text] [Related]  

  • 14. Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study.
    Harrison-Woolrych M; Paterson H; Tan M
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1086-92. PubMed ID: 23926076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline for smoking cessation.
    Harrison-Woolrych M
    BMJ; 2012 Nov; 345():e7547. PubMed ID: 23138037
    [No Abstract]   [Full Text] [Related]  

  • 16. Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme.
    Tan M; Harrison-Woolrych M
    Eur J Clin Pharmacol; 2013 May; 69(5):1195-6. PubMed ID: 23232978
    [No Abstract]   [Full Text] [Related]  

  • 17. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
    Svanström H; Pasternak B; Hviid A
    BMJ; 2012 Nov; 345():e7176. PubMed ID: 23138033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.